Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 27;15(3):779.
doi: 10.3390/cancers15030779.

Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer

Jakub Liu  1 , Magdalena Mroczek  2 , Anna Mach  3   4 , Maria Stępień  5 , Angelika Aplas  4 , Bartosz Pronobis-Szczylik  4 , Szymon Bukowski  4 , Magda Mielczarek  1   6 , Ewelina Gajewska  4 , Piotr Topolski  4 , Zbigniew J Król  4 , Joanna Szyda  1   6 , Paula Dobosz  4
Affiliations
Review

Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer

Jakub Liu et al. Cancers (Basel). .

Abstract

The number of cases of pancreatic cancers in 2019 in Poland was 3852 (approx. 2% of all cancers). The course of the disease is very fast, and the average survival time from the diagnosis is 6 months. Only <2% of patients live for 5 years from the diagnosis, 8% live for 2 years, and almost half live for only about 3 months. A family predisposition to pancreatic cancer occurs in about 10% of cases. Several oncogenes in which somatic changes lead to the development of tumours, including genes BRCA1/2 and PALB2, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1, are involved in pancreatic cancer. Between 4% and 10% of individuals with pancreatic cancer will have a mutation in one of these genes. Six percent of patients with pancreatic cancer have NTRK pathogenic fusion. The pathogenesis of pancreatic cancer can in many cases be characterised by homologous recombination deficiency (HRD)-cell inability to effectively repair DNA. It is estimated that from 24% to as many as 44% of pancreatic cancers show HRD. The most common cause of HRD are inactivating mutations in the genes regulating this DNA repair system, mainly BRCA1 and BRCA2, but also PALB2, RAD51C and several dozen others.

Keywords: genetics; genomics; molecular therapies; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interest to disclose.

References

    1. Didkowska J., Wojciechowska U., Olasek P., Caetano Dos Santos F.L., Michałek I.M. Cancer in Poland in 2019. Ministry of Health; Warsaw, Poland: 2021.
    1. Michaud D.S. Epidemiology of Pancreatic Cancer. Minerva Chir. 2004;59:99–111. - PubMed
    1. Poruk K.E., Firpo M.A., Adler D.G., Mulvihill S.J. Screening for Pancreatic Cancer. Ann. Surg. 2013;257:17–26. doi: 10.1097/SLA.0b013e31825ffbfb. - DOI - PMC - PubMed
    1. Lampe P., Grabarczyk A., Kuśnierz K. Theoretical and Realistic Aspects in the Diagnosis of Pancreatic Cancer. Postep. Nauk. Med. 2015;28:4–10.
    1. Vujasinovic M., Dugic A., Maisonneuve P., Aljic A., Berggren R., Panic N., Valente R., Pozzi Mucelli R., Waldthaler A., Ghorbani P., et al. Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. J. Clin. Med. 2020;9:3720. doi: 10.3390/jcm9113720. - DOI - PMC - PubMed